日科化學(300214.SZ):擬出資2880萬元參設合資公司 擬投建鋰電池電解液項目
格隆匯1月28日丨日科化學(300214.SZ)公佈,公司根據公司戰略需要,擬使用自有資金2880萬元與山東宏旭化學股份有限公司(“宏旭化學”)、山東恆裕通投資有限公司(“恆裕通投資”)共同成立東營市匯能達新材料科技有限公司(具體名稱以工商登記為準,簡稱“合資公司”),合資公司註冊資本為人民幣8000萬元,合資公司成立後擬投資建設鋰電池電解液項目,主要經營產品有碳酸乙烯酯(EC)、氯代碳酸乙烯酯(CEC)、碳酸亞乙烯酯(VC)、氟代碳酸乙烯酯(FE)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.